Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
BMC Nephrol ; 22(1): 384, 2021 11 17.
Artigo em Inglês | MEDLINE | ID: mdl-34789170

RESUMO

BACKGROUND: Hemodialysis patients are among high-risk groups for COVID-19. Africa is the continent with the lowest number of cases in the general population but we have little information about the disease burden in dialysis patients. OBJECTIVES: This study aimed to describe the seroprevalence of SARS-CoV-2 antibodies in the hemodialysis population of Senegal. PATIENTS AND METHODS: We conducted a multicenter cross-sectional survey, between June and September 2020 involving 10 public dialysis units randomly selected in eight regions of Senegal. After seeking their consent, we included 303 patients aged ≥ 18 years and hemodialysis for ≥ 3 months. Clinical symptoms and biological parameters were collected from medical records. Patients' blood samples were tested with Abbott SARS-CoV-2 Ig G assay using an Architect system. Statistical tests were performed with STATA 12.0. RESULTS: Seroprevalence of SARS-CoV-2 antibodies was 21.1% (95% CI = 16.7-26.1%). We noticed a wide variability in SARS-CoV-2 seroprevalence between regions ranging from 5.6 to 51.7%. Among the 38 patients who underwent nasal swab testing, only six had a PCR-confirmed infection and all of them did seroconvert. Suggestive clinical symptoms were reported by 28.1% of seropositive patients and the majority of them presented asymptomatic disease. After multivariate analysis, a previous contact with a confirmed case and living in a high population density region were associated with the presence of SARS-CoV-2 antibodies. CONCLUSION: This study presents to our knowledge the first seroprevalence data in African hemodialysis patients. Compared to data from other continents, we found a higher proportion of patients with SARS-CoV-2 antibodies but a lower lethality rate.


Assuntos
Anticorpos Antivirais/sangue , COVID-19/epidemiologia , Diálise Renal , SARS-CoV-2/imunologia , Adolescente , Adulto , Idoso , COVID-19/sangue , COVID-19/complicações , Busca de Comunicante , Estudos Transversais , Escolaridade , Feminino , Geografia Médica , Inquéritos Epidemiológicos , Humanos , Imunoglobulina G/sangue , Falência Renal Crônica/complicações , Falência Renal Crônica/terapia , Masculino , Pessoa de Meia-Idade , Densidade Demográfica , Prevalência , Senegal/epidemiologia , Estudos Soroepidemiológicos , Avaliação de Sintomas , Adulto Jovem
2.
Saudi J Kidney Dis Transpl ; 24(5): 1068-72, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24029286

RESUMO

Chronic kidney disease (CKD) is frequently described in elders. This study describes the epidemiological patterns of patients ≥60 years old admitted in our department during one year. The prevalence of CKD was 10.8% (60/552). The mean age of the patients was 70.5 years (60-84 years) and the sex ratio (male:female) was 1.08. The mean serum creatinine level was 7.10 mg/dL (1.31-25.0 mg/dL) and more than two-third of the patients presented CKD stage 4-5. Causes of CKD were dominated by hypertension (30%) and diabetes (25%). Prevalence of inpatients aged 60-69 years old was higher than in those ≥80 years old but lower than that in patients aged 70-79 years. At admission, 83.3% of the patients were hypertensive, 75% were anemic and 13% presented proteinuria. The main co-morbidities associated with CKD were neoplasms (17% of cases), chronic heart disease (15% of cases) and pneumonia (15% of cases). Furosemide was prescribed in 55% of the patients, calcium channel blockers in 23% of the patients and ACE inhibitors in 20% of the patients. Renal replacement therapy was not performed for any patient. Evolution was favorable in the majority of patients (77%), but 23% died mainly because of uremia and infections.


Assuntos
Insuficiência Renal Crônica/epidemiologia , África Ocidental/epidemiologia , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Feminino , Cardiopatias/epidemiologia , Humanos , Hipertensão/epidemiologia , Masculino , Pessoa de Meia-Idade , Neoplasias/epidemiologia , Pneumonia/epidemiologia , Prevalência , Estudos Retrospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA